Ranolazine stabilizes cardiac ryanodine receptors: a novel mechanism for the suppression of early afterdepolarization and torsades de pointes in long QT type 2.

doi:10.1016/j.hrthm.2012.01.010

Paper

Ranolazine stabilizes cardiac ryanodine receptors: a novel mechanism for the suppression of early afterdepolarization and torsades de pointes in long QT type 2.

Published Jun 1, 2012 · A. Parikh, Rajkumar Mantravadi, D. Kozhevnikov

Heart rhythm

Q1 SJR score

73

Citations

3

Influential Citations

Full textSemantic Scholar

Abstract

Abstract hidden due to publisher request; this does not indicate any issues with the research. Click the full text link above to read the abstract and view the original source.

In Vitro Study

Highly Cited

Study Snapshot

Ranolazine suppresses early afterdepolarization and torsades de pointes in long QT type 2 by stabilizing cardiac ryanodine receptors, a novel mechanism for its antiarrhythmic effects.

PopulationOlder adults (50-71 years)

Sample size24

MethodsObservational

OutcomesBody Mass Index projections

ResultsSocial networks mitigate obesity in older groups.

Ranolazine stabilizes cardiac ryanodine receptors: a novel mechanism for the suppression of early afterdepolarization and torsades de pointes in long QT type 2.

References

Citations